UA81744C2 - Фармацевтическая композиция, которая содержит аминопроизводную 2,3-дигидрофталазин-1,4-диона, и способ коррекции иммунной системы организма - Google Patents
Фармацевтическая композиция, которая содержит аминопроизводную 2,3-дигидрофталазин-1,4-диона, и способ коррекции иммунной системы организма Download PDFInfo
- Publication number
- UA81744C2 UA81744C2 UA2003021833A UA2003021833A UA81744C2 UA 81744 C2 UA81744 C2 UA 81744C2 UA 2003021833 A UA2003021833 A UA 2003021833A UA 2003021833 A UA2003021833 A UA 2003021833A UA 81744 C2 UA81744 C2 UA 81744C2
- Authority
- UA
- Ukraine
- Prior art keywords
- amino
- dione
- dihydrophthalazine
- drug
- composition according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 6
- 210000000987 immune system Anatomy 0.000 title claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 150000001412 amines Chemical class 0.000 title abstract description 5
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000000403 immunocorrecting effect Effects 0.000 claims description 6
- SCHUENIUEDOXQS-UHFFFAOYSA-N 5-amino-2,3-dihydrophthalazine-1,4-dione;hydrochloride Chemical group Cl.O=C1NNC(=O)C2=C1C(N)=CC=C2 SCHUENIUEDOXQS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 229910052788 barium Inorganic materials 0.000 claims 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims 2
- -1 6-phenyl-amino-2,3-dihydrophthalazine-1,4-dione Chemical compound 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 59
- 239000000126 substance Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 34
- 230000000694 effects Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 159000000000 sodium salts Chemical class 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- VOQOISCWQWDUCM-UHFFFAOYSA-N 5-(methylamino)-2,3-dihydrophthalazine-1,4-dione Chemical compound O=C1NNC(=O)C2=C1C(NC)=CC=C2 VOQOISCWQWDUCM-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000000686 immunotropic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- IQFKNYLTBAWCKN-UHFFFAOYSA-N 5-aminophthalazine-1,4-dione Chemical class O=C1N=NC(=O)C2=C1C=CC=C2N IQFKNYLTBAWCKN-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 241001247437 Cerbera odollam Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 244000180111 Eucalyptus platypus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- RPYIJXJOUPRNQM-UHFFFAOYSA-N O.O.[Na].Nn1[nH]c(=O)c2ccccc2c1=O Chemical compound O.O.[Na].Nn1[nH]c(=O)c2ccccc2c1=O RPYIJXJOUPRNQM-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010044279 T-activin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- AFKDOBHQNHKDEE-UHFFFAOYSA-I aluminum;magnesium;ethyl 4-aminobenzoate;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3].CCOC(=O)C1=CC=C(N)C=C1 AFKDOBHQNHKDEE-UHFFFAOYSA-I 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- YTLQFZVCLXFFRK-UHFFFAOYSA-N bendazol Chemical compound N=1C2=CC=CC=C2NC=1CC1=CC=CC=C1 YTLQFZVCLXFFRK-UHFFFAOYSA-N 0.000 description 1
- 229950000900 bendazol Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2000120330/14A RU2167659C1 (ru) | 2000-08-02 | 2000-08-02 | Способ коррекции иммунной системы живого организма |
PCT/IB2001/001293 WO2002009681A2 (en) | 2000-08-02 | 2001-07-20 | A method for correcting the immune system of live body |
Publications (1)
Publication Number | Publication Date |
---|---|
UA81744C2 true UA81744C2 (ru) | 2008-02-11 |
Family
ID=20238611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2003021833A UA81744C2 (ru) | 2000-08-02 | 2001-07-20 | Фармацевтическая композиция, которая содержит аминопроизводную 2,3-дигидрофталазин-1,4-диона, и способ коррекции иммунной системы организма |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030195183A1 (ru) |
EP (1) | EP1315497A2 (ru) |
AU (1) | AU2001270934A1 (ru) |
RU (1) | RU2167659C1 (ru) |
UA (1) | UA81744C2 (ru) |
WO (1) | WO2002009681A2 (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1203587B1 (en) * | 2000-03-28 | 2010-07-14 | Abidov, Musea Tazhudinovich | A medicament and method for the production thereof |
AU2002220241A1 (en) * | 2000-12-01 | 2002-06-11 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
US7326690B2 (en) * | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
US8592421B2 (en) | 2003-08-04 | 2013-11-26 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
MXPA06005657A (es) * | 2003-11-19 | 2006-08-23 | Array Biopharma Inc | Inhibidores heterociclicos de mek y metodos para usarlos. |
US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
CN102321030A (zh) * | 2005-05-18 | 2012-01-18 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
WO2008129029A1 (en) * | 2007-04-23 | 2008-10-30 | Novartis Ag | Phthalazine and isoquinoline derivatives with slp receptor modulating activities |
US8497269B2 (en) | 2008-10-10 | 2013-07-30 | Amgen Inc. | Phthalazine compounds as p38 map kinase modulators and methods of use thereof |
WO2010042646A1 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof |
DK2542535T3 (da) | 2010-03-01 | 2014-07-28 | Metriopharm Ag | Krystalformer af 5-amino-2,3-dihydrophthalazin-1,4-dion-natriumsalt, farmaceutiske præparater indeholdende disse samt fremgangsmåder til deres fremstilling |
RU2550879C1 (ru) * | 2014-03-31 | 2015-05-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ставропольский государственный аграрный университет" | Способ окраски мазков крови для микроскопического определения структурной организации и фаз активности клеток |
RU2635769C1 (ru) * | 2017-02-08 | 2017-11-15 | Адмир Мусаевич Абидов | Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения |
US20210379063A1 (en) * | 2018-10-26 | 2021-12-09 | Immunopharma Plus D.O.O. | Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2654689A (en) * | 1950-10-28 | 1953-10-06 | Ethyl Corp | N, n'-phthalyl hydrazine fungicidal composition |
JPS5334785A (en) * | 1976-09-09 | 1978-03-31 | Mitsubishi Chem Ind Ltd | 1-substituted-4-halogeno-5, 6, 7, 8-tetrahydrophthalazines |
GB2244704B (en) * | 1990-05-04 | 1995-05-17 | Consultants Suppliers Limited | Substituted benzene compounds |
JPH0736013B2 (ja) * | 1991-04-27 | 1995-04-19 | 一男 田畑 | 潜血検出用試薬 |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
RU2113222C1 (ru) * | 1997-09-30 | 1998-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Иммуномодулирующее средство |
EP1203587B1 (en) * | 2000-03-28 | 2010-07-14 | Abidov, Musea Tazhudinovich | A medicament and method for the production thereof |
-
2000
- 2000-08-02 RU RU2000120330/14A patent/RU2167659C1/ru not_active IP Right Cessation
-
2001
- 2001-07-20 EP EP01949822A patent/EP1315497A2/en not_active Withdrawn
- 2001-07-20 AU AU2001270934A patent/AU2001270934A1/en not_active Abandoned
- 2001-07-20 WO PCT/IB2001/001293 patent/WO2002009681A2/en not_active Application Discontinuation
- 2001-07-20 UA UA2003021833A patent/UA81744C2/ru unknown
-
2003
- 2003-01-21 US US10/348,494 patent/US20030195183A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030195183A1 (en) | 2003-10-16 |
WO2002009681A3 (en) | 2002-05-16 |
RU2167659C1 (ru) | 2001-05-27 |
AU2001270934A1 (en) | 2002-02-13 |
WO2002009681A2 (en) | 2002-02-07 |
EP1315497A2 (en) | 2003-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA81744C2 (ru) | Фармацевтическая композиция, которая содержит аминопроизводную 2,3-дигидрофталазин-1,4-диона, и способ коррекции иммунной системы организма | |
Baxby et al. | Human cryptosporidiosis: a possible case of hospital cross infection. | |
Ogilvie et al. | Immunity in the parasitic relationship between helminths and hosts | |
Daugschies et al. | Eimeriosis in cattle: current understanding | |
Rose et al. | Immunity to coccidiosis: T-lymphocyte-or B-lymphocyte-deficient animals | |
Smith et al. | Chronic giardiasis: studies on drug sensitivity, toxin production, and host immune response | |
Lindenbaum | Malabsorption during and after recovery from acute intestinal infection | |
JP2009007368A (ja) | 下痢治療におけるクロトリマゾールおよび関連化合物の使用 | |
JPH10505358A (ja) | クロストリジウム・ディフィシル関連疾患の治療処置 | |
Rothwell et al. | The role of pharmacologically-active amines in resistance to Trichostrongylus colubriformis in the guinea-pig | |
EA003458B1 (ru) | Усиление активности оксазолидиноновых антибактериальных агентов в результате применения производных аргинина | |
RO122247B1 (ro) | Compoziţii farmaceutice de tizoxanidă şi nitazoxanidă | |
JP3739802B2 (ja) | チゾキサニドおよびニタゾキサニドの薬剤の合成物 | |
Frenkel | Infection and Immunity in Hamsters1 | |
Stogaus et al. | Is oral levamisole immunostimulation in rats mediated by reduced levels of free plasma corticosterone? | |
Lemke | Antiparasitic agents | |
Botros et al. | The immunological aspects of praziquantel in unsensitized mice with experimentally induced schistosome pulmonary granuloma | |
Nehra et al. | Parasites in the cardiovascular system | |
US6869602B2 (en) | Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells | |
RU2772024C1 (ru) | Препарат для лечения собак, больных кокцидиозом, трихомонозом, лямблиозом и амебиазом | |
Petru et al. | Arizona hinshawii infection of an atherosclerotic abdominal aorta | |
Pleass et al. | The role of adult worms in suppressing functional protective immunity to Heligmosomoides polygyrus bakeri challenge infections | |
RU2811772C2 (ru) | Способ селективного разрушения макрофагов в клеточной суспензии и целостном организме с помощью препаратов коллоидного серебра - протаргола и колларгола | |
RU2780141C1 (ru) | Препарат для лечения собак, больных трихомонозом, лямблиозом, амебиазом и токсокарозом | |
JP3055039B2 (ja) | 消化管のリンパ球及びマイトジエンの活性賦活剤 |